In recent years, studies have demonstrated that sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a renal protective effect and reduce the incidence of cardiovascular events in patients with diabetic nephropathy (DKD) (Perkovic et al., 2019; Bhatt et al., 2021; Cherney et al., 2023). Here, SLC5A2 is linked to diabetic kidney disease.